Single Dose Crossover Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules in Healthy Male Volunteers Following Administration of a 50 mg Dose / Fasted and Fed States

Trial Profile

Single Dose Crossover Comparative Bioavailability Study of BIA 9-1067 25 mg Capsules in Healthy Male Volunteers Following Administration of a 50 mg Dose / Fasted and Fed States

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Jun 2017

At a glance

  • Drugs Opicapone (Primary)
  • Indications Parkinson's disease
  • Focus Pharmacokinetics
  • Sponsors Bial
  • Most Recent Events

    • 27 Jun 2017 Results presented at the 3rd Congress of the European Academy of Neurology
    • 08 Jun 2017 Results (n=40) assessing effect of food on the pharmacokinetics and pharmacodynamics of opicapone after single and repeated doses using patient data from NCT02071823 and NCT03116308 trials, presented at the 21st International Congress of Parkinson's Disease and Movement Disorders
    • 14 Apr 2014 New source identified and integrated; ClinicalTrials.gov record (NCT02071823)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top